436 related articles for article (PubMed ID: 1967895)
1. New concepts in the treatment of Parkinson's disease.
Ahlskog JE; Wilkinson JM
Am Fam Physician; 1990 Feb; 41(2):574-84. PubMed ID: 1967895
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Parkinson's disease. From theory to practice.
Ahlskog JE
Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Parkinson's disease.
Lieberman A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
[TBL] [Abstract][Full Text] [Related]
4. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
5. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Zimmerman TR; Sage JI; Lang AE; Mark MH
Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
[TBL] [Abstract][Full Text] [Related]
6. Treatment of early Parkinson's disease: are complicated strategies justified?
Ahlskog JE
Mayo Clin Proc; 1996 Jul; 71(7):659-70. PubMed ID: 8656708
[TBL] [Abstract][Full Text] [Related]
7. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
Rinne UK
Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
[No Abstract] [Full Text] [Related]
8. Moderate Parkinson's disease. Strategies for maximizing treatment.
Silverstein PM
Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
[TBL] [Abstract][Full Text] [Related]
9. An integrated approach to patient management in Parkinson's disease.
Lieberman A
Neurol Clin; 1992 May; 10(2):553-65. PubMed ID: 1350053
[TBL] [Abstract][Full Text] [Related]
10. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
11. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
[TBL] [Abstract][Full Text] [Related]
12. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
13. Medical treatment of Parkinson's disease.
Ahlskog JE
Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
[No Abstract] [Full Text] [Related]
14. Treatment of Parkinson's disease.
Eadie MJ
Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Brannan T; Yahr MD
Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
[TBL] [Abstract][Full Text] [Related]
16. Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Chase TN; Baronti F; Fabbrini G; Heuser IJ; Juncos JL; Mouradian MM
Neurology; 1989 Nov; 39(11 Suppl 2):7-10; discussion 19. PubMed ID: 2685653
[TBL] [Abstract][Full Text] [Related]
17. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
19. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
20. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]